Trials / Unknown
UnknownNCT04615468
A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）
A Single-arm, Open-label, Multi-center, Phase II Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with relapse/refactory peripheral T-cell lymphoma who have received at least 1 lines of therapeutic schedules. TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-B3525 | TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle. |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2021-10-31
- Completion
- 2022-10-31
- First posted
- 2020-11-04
- Last updated
- 2020-11-04
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04615468. Inclusion in this directory is not an endorsement.